XBiotech Inc. (NASDAQ:XBIT)’s share price rose 3.4% during mid-day trading on Tuesday . The company traded as high as $15.39 and last traded at $15.30, with a volume of 85,550 shares traded. The stock had previously closed at $14.79.

XBIT has been the subject of a number of analyst reports. Noble Financial reissued a “buy” rating and set a $24.00 target price on shares of XBiotech in a research note on Thursday, May 19th. Zacks Investment Research downgraded XBiotech from a “buy” rating to a “hold” rating in a research note on Wednesday, April 6th.

The stock has a 50-day moving average price of $17.22 and a 200 day moving average price of $11.89. The firm’s market capitalization is $496.25 million.

In other news, Director W Thorpe Mckenzie acquired 20,000 shares of the stock in a transaction that occurred on Thursday, May 26th. The stock was purchased at an average cost of $13.96 per share, with a total value of $279,200.00. Following the completion of the acquisition, the director now directly owns 3,898,600 shares in the company, valued at $54,424,456. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. The Company primarily focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.